Specialty drugs have been a major cost driver for years, but 2026 marks a significant shift in both scale and urgency. With GLP‑1 medications expanding into new indications, gene therapies entering the market at record pace, and oncology drugs continuing to rise in both cost and utilization, specialty medications are projected to account for more than 60% of total pharmacy spending this year. That’s a dramatic change for employers, especially considering that specialty drugs represent fewer than 5% of total prescriptions.
This shift is not simply a continuation of past trends — it reflects a new era in which breakthrough therapies, precision medicine, and chronic‑condition management are converging to reshape the pharmacy landscape. Employers are finding that strategies that worked even a few years ago are no longer sufficient to manage the financial and operational impact.
What’s Driving the Spike
The most visible driver is the continued surge in GLP‑1 medications. Originally prescribed for diabetes, these drugs are now widely used for weight management and are expected to receive additional approvals for cardiovascular and metabolic conditions. As demand grows, employers are weighing whether to cover these medications broadly, how to structure utilization controls, and how to balance short‑term costs with potential long‑term health improvements such as reduced obesity‑related claims.
Gene therapies are also reshaping the cost curve. Many of these treatments exceed $1 million per patient, and more are entering the market each quarter. While they can offer life‑changing outcomes, they also introduce significant financial volatility. A single claim can dramatically affect a self‑funded employer’s annual spend, even with stop‑loss protection in place.
Oncology drugs add another layer of complexity. Targeted therapies and immunotherapies continue to improve survival rates, but they often come with high price tags and require ongoing monitoring. Employers are increasingly turning to centers of excellence (COEs) to ensure consistent, high‑quality care and reduce unnecessary variation in treatment costs.
Rethinking PBM Relationships
Pharmacy benefit managers (PBMs) are under heightened scrutiny, and many employers are reevaluating their contracts. Transparency has become a priority, with organizations seeking clearer insight into rebate structures, administrative fees, and the true net cost of medications. Some employers are considering pass‑through PBMs, while others are exploring carve‑out models that separate pharmacy benefits from the medical plan.
Key areas employers are reviewing include:

Rebate and fee transparency
Spread pricing practices
Reporting and data‑sharing capabilities

These reviews are prompting many employers to renegotiate terms, seek more frequent reporting, or explore alternative PBM models that offer greater visibility and alignment with plan goals.
The Growing Role of Data and Predictive Tools
Predictive analytics is becoming a practical tool for employers of all sizes. These platforms help identify high‑risk populations earlier, anticipate future claims, and support targeted care management. When combined with COEs and improved care coordination, analytics can help reduce avoidable high‑cost events and improve outcomes for employees with chronic or complex conditions.
Employers are also using data to evaluate the long‑term value of specialty medications. For example, some GLP‑1 programs now integrate coaching, nutrition support, and biometric monitoring to improve adherence and maximize clinical benefit.
Communication Matters More Than Ever
Employees often struggle to understand why certain medications require review or why coverage criteria change. Clear, empathetic communication can reduce frustration, improve adherence, and build trust in the benefits program. Employers are updating plan materials, offering decision‑support tools, and working with vendors to simplify the member experience. Transparent communication also helps employees understand the value of programs such as COEs, care management, and step therapy.
Looking Ahead
Specialty drug management will remain a defining challenge throughout 2026. Employers that take a proactive, data‑driven approach — blending financial protection, clinical oversight, and thoughtful communication — will be best positioned to manage rising costs while supporting high‑quality care for their workforce. As innovation accelerates, the employers who adapt early will be better equipped to navigate the next wave of specialty‑drug evolution.
For more Employee Benefits resources, contact INSURICA today.
Copyright © 2026 Smarts Publishing. This is not intended to be exhaustive nor should any discussion or opinions be construed as legal advice. Readers should contact legal counsel or an insurance professional for appropriate advice.